Folate deficiency induced hyperhomocysteinemia changes the expression of thrombosis-related genes

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 4, 2006, Pages 293-301

  Ebbesen, Liselotte S ^a,b   Olesen, Sanne H ^a   Kruhøffer, Mogens ^a   Ingerslev, Jørgen ^a   Ørntoft, Torben F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

Blood coagulation; Gene expression analysis; Homocysteine; Thrombosis

Indexed keywords

BETA3 INTEGRIN; BLOOD CLOTTING FACTOR 13A; CD31 ANTIGEN; GLYCOPROTEIN; GLYCOPROTEIN V; KALLIKREIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAP1 PROTEIN; RAP1B PROTEIN; RNA; SELECTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BUFFY COAT CELL; CELL; CELL ACTIVATION; CELL CONTACT; CONTACT ACTIVATION; CONTROLLED STUDY; DNA MICROARRAY; FIBRINOLYSIS; FOLIC ACID DEFICIENCY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; HYPERHOMOCYSTEINEMIA; LEUKOCYTE ROLLING; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; ANTIGENS, CD31; DISEASE MODELS, ANIMAL; FOLIC ACID DEFICIENCY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HYPERHOMOCYSTEINEMIA; INTEGRIN BETA3; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; RAP GTP-BINDING PROTEINS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

EID: 33646774995     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000224849.19754.85     Document Type: Article

References (42)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049-1057.
2. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5:229-232.
3. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-236.
4. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158:862-867.
5. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34:632-636.
6. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874-877.
7. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003; 102:1363-1366.
8. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
9. Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22:1042-1045.
10. Michalis LK, Pappas K, Tweddel A, Kolaitis N, Katsouras CS, Loukas S, et al. Relatively low red cell folate levels and acute coronary syndromes. Coron Artery Dis 2001; 12:665-668.
11. De Bree A, Verschuren WMM, Kromhout D, Kluijtmans LAJ, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54:599.
12. Ebbesen LS, Christiansen K, Ingerslev J. Hyperhomocysteinemia due to folate deficiency is thrombogenic in rats. J Nutr 2003; 133:2250-2255.
13. Ebbesen LS, Ingerslev J. Folate deficiency induced hyperhomocysteinemia attenuates, and folic acid supplementation restores, the functional activities of rat coagulation factors XII, X, and II. J Nutr 2005; 135:18936-1840.
14. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost 1987; 58:1078-1084.
15. Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95:14470-14475.
16. Lockhart DJ, Dong H, Byrne MC, Follettie MT, Gallo MV, Chee MS, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14:1675-1680.
17. Davi G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P, et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001; 104:1124-1128.
18. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11:1157-1168.
19. Ungvari Z, Sarkadi-Nagy E, Bagi Z, Szollar L, Koller A. Simultaneously increased TxA(2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia [in process citation]. Arterioscler Thromb Vasc Biol 2000; 20:1203-1208.
20. Fischer TH, Gatling MN, McCormick F, Duffy CM, White GC. Incorporation of Rap 1b into the platelet cytoskeleton is dependent on thrombin activation and extracellular calcium. J Biol Chem 1994; 269:17257-17261.
21. Bertoni A, Tadokoro S, Eto K, Pampori N, Parise LV, White GC, Shattil SJ. Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem 2002; 277:25715-25721.
22. Berndt MC, Shen Y, Dopheide SM, Gardiner EE, Andrews RK. The vascular biology of the glycoprotein Ib-IX-V complex. Thromb Haemost 2001; 86:178-188.
23. Varon D, Jackson DE, Shenkman B, Dardik R, Tamarin I, Savion N, Newman PJ. Platelet/endothelial cell adhesion molecule-1 serves as a costimulatory agonist receptor that modulates integrin-dependent adhesion and aggregation of human platelets. Blood 1998; 91:500.
24. Nielsen VG, Gurley WQ Jr, Burch TM. The impact of factor XIII on coagulation kinetics and clot strength determined by thrombelastography. Anesth Analg 2004; 99:120-123.
25. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003; 1:300-306.
26. Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I, et al. Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88:799-804.
27. Schreiner PJ, Wu KK, Malinow MR, Stinson VL, Szklo M, Nieto FJ, Heiss G. Hyperhomocyst(e)inemia and hemostatic factors: The Atherosclerosis Risk in Communities Study. Ann Epidemiol 2002; 12:228-236.
28. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91:2873-2879.
29. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci U S A 1992; 89:10193-10197.
30. Ichinose A, Fujikawa K, Suyama T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 1986; 261:3486-3489.
31. Miles LA, Greengard JS, Griffin JH. A comparison of the abilities of plasma kallikrein, beta-Factor XIIa. Factor XIa and urokinase to activate plasminogen. Thromb Res 1983; 29:407-417.
32. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44:1-80.
33. Kemme M, Podlich D, Raidoo DM, Snyman C, Naidoo S, Bhoola KD. Identification of immunoreactive tissue prokallikrein on the surface membrane of human neutrophils. Biol Chem 1999; 380:1321-1328.
34. Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 1973; 138:1564-1583.
35. Griffin JH, Cochrane CG. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci U S A 1976; 73:2554-2558.
36. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-943.
37. Ross R. Atherosclerosis: an inflammatory disease [see comments]. N Engl J Med 1999; 340:115-126.
38. Patel KD, Cuvelier SL, Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2002; 14:73-81.
39. Rainer TH. L-selectin in health and disease. Resuscitation 2002; 52:127-141.
40. Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000; 96:966-972.
41. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Association between B vitamin intake and plasma homocysteine concentration in the general Dutch population aged 20-65 y. Am J Clin Nutr 2001; 73:1027-1033.
42. James SJ, Melnyk S, Pogribna M, Pogribny IP, Caudill MA. Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 2002; 132:2361S-2366S.